<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> (MET) is the first-line agent in treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>However, MET has been associated with <z:hpo ids='HP_0003128'>lactic acidosis</z:hpo> (MALA), a potential but rare complication which has influenced treatment strategies in decades </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, guidelines have been changed in regards of age and <z:hpo ids='HP_0001635'>heart failure</z:hpo> and the contradiction of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> has been debated </plain></SENT>
<SENT sid="3" pm="."><plain>This article identifies potential risk groups and situations that would benefit from a temporary interruption in the MET treatment </plain></SENT>
</text></document>